PolyPeptide Reports Strong Preliminary 2025 Results With Higher Revenue And Profit

PolyPeptide reported preliminary FY2025 results with revenue of ~EUR 389 million, up ~15.6% year-over-year driven primarily by demand for metabolic therapeutics, and an improved EBITDA margin of an estimated 11–12% versus 7.5% a year earlier. Capital expenditures were just over EUR 100 million, year-end cash stood at EUR 75 million with EUR 51 million available under its revolving credit facility, and the stock closed up 10.07% on the SIX Swiss Exchange, reflecting positive investor reaction to the stronger profitability and solid liquidity position.

Analysis

Market structure: PolyPeptide (PPGN.SW) is a direct winner — revenue +15.6% and EBITDA margin expanding to ~11–12% implies improving pricing power in peptide CDMO niches (metabolic therapeutics). Incumbent large CDMOs (e.g., Lonza) face selective margin pressure where specialist peptide capacity is scarce; shortages would sustain premium pricing for niche providers. At the cross-asset level, stronger equity performance in peptide/CDMO names should modestly tighten credit spreads for smaller biotech manufacturers and lift implied vol in equity options; FX risk (EUR/CHF) can materially swing reported EUR revenue in CHF terms.

Risk assessment: Key tail risks are manufacturing contamination or regulatory GMP failures, abrupt loss of a large customer (top-3 customer concentration), and mis-timed capacity spend — capex ~€100m (~25% of revenue) is large and creates execution risk. Immediate (days) risk: momentum unwind after a preliminary release; short-term (weeks–months): order timing and guidance release; long-term (years): payback on capex and sustainability of margin improvement. Hidden dependencies include contract phasing and currency mix; catalysts are full FY filing, FY26 guidance, major customer renewals and inspection outcomes.

Trade implications: Favor targeted exposure to peptide specialists. Tactical: establish a modest long in PPGN.SW or use a defined-cost call spread to limit downside; consider a relative-value pair long PPGN.SW vs short LONN.SW to isolate peptide upside. Avoid chasing post-jump; prefer entries on 5–15% pullbacks or after full-year disclosure; scale out on +25–30% moves or on any weakening guidance.

Contrarian angles: The market may be extrapolating the margin step-change; margins could normalize as capacity ramps and pricing competition increases. The 10% intraday move on preliminary numbers risks being overdone absent detailed guidance — watch top-3 customer revenue share and capex cadence. Historical parallels: specialist CDMO spikes that reversed when single-customer dynamics unwound; if top customer >40% of revenue or capex delays >6 months, downside could be sharp.

Key Decisions for Investors

• Establish a 2–3% long position in PolyPeptide (PPGN.SW) within 2 weeks or on a pullback of 5–15%; set a hard stop at -10% and a profit-taking target at +25% over a 6–12 month horizon; trim half if position rallies >30% within 3 months.
• Implement a relative-value pair: long PPGN.SW (notional 1x) and short Lonza (LONN.SW) 0.5–1x by notional for 6–12 months to capture peptide-specific outperformance; exit if spread narrows >15% or either company issues materially divergent guidance.
• Use options to define risk: buy a 6–9 month call spread on PPGN.SW (buy ~ATM call, sell call ~+20–25% strike) sized to risk 1–2% of portfolio; alternatively sell 1-month OTM puts for premium if willing to own at a 8–12% lower price.
• Reallocate +1–2% overweight to peptide-focused CDMOs and reduce broad CDMO exposure (e.g., TMO, CTLT) by 1% to favor niche pricing power; if EUR/CHF depreciates >3% from current levels, reduce PPGN exposure by 50% to limit FX translation risk.
• Monitor within 30–60 days: full FY results, FY26 guidance, top-3 customer revenue %, and capex schedule. If top-3 customers account for >40% of revenue or capex slippage >6 months, liquidate position immediately.